Shield announces results from it’s Pre-Submission meeting with the FDA and confirms plans to submit a New Drug Application for Feraccru.

6 Apr 2018

Shield Therapeutics announces results from it’s Pre-Submission meeting with the FDA and confirms plans to submit a New Drug Application for Feraccru. This press release provides a strategic review update and announces the appointment of a Non-Executive Director.  For further details please see the press release attached.

STX_CKD Update from FDA post pre-NDA meeting

Webcast and conference call for analysts at 1pm BST today

Carl Sterritt, Chief Executive Officer, Dr Karl Keegan, Chief Financial Officer and Dr Mark Sampson, Chief Medical Officer, will host a live conference call and webcast for analysts at 1pm BST today, 6 April 2018, to discuss this announcement.

Dial in details:

Location Purpose Phone Number
United Kingdom Participant +44 (0)330 336 9105
United States Participant +1 646-828-8156

The participation code is: 8668739

To access the audio webcast, please follow this link or alternatively visit our  investor relations page.

Back to news

London, UK

16 Upper Woburn Place
Euston
London, WC1H 0AF

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

einfo@shieldtx.com

Berlin, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin
Germany

t+44 (0) 207 186 8500

einfo@shieldtx.com